New Biomarker Detection Method for Neuroscience Researchers
New Biomarker Detection Method for Neuroscience Researchers
The ability to accurately detect and measure biomarkers is critical to advancing research and developing effective treatments for neurodegenerative diseases. However, current diagnostic techniques often fall short due to limitations in sensitivity and specificity, especially when detecting biomarkers in low concentrations. This is why the recent development of Binding Oligo Ladder Detection (BOLD) holds such promise for biomarker research for neurodegenerative diseases.
Using Exazym® to Detect pTau(181) in Human Plasma
This white paper is based on recent advancements in neuroscience research. The ability to accurately detect and measure biomarkers is critical to advancing research and developing effective treatments for neurodegenerative diseases. However, current diagnostic techniques often fall short due to limitations in sensitivity and specificity, especially when detecting biomarkers in low concentrations. Now, BOLD technology allows for attomole-level detection of low-abundance biomarkers using existing workflows and equipment.
The Real-World Impact of Applying BOLD to Neuroscience Research
In this white paper, you’ll see the strides one team has made in identifying crucial neurologic biomarkers from blood samples. Exazym®’s BOLD technology offers a groundbreaking solution, enabling:
- 50x improved sensitivity in biomarker detection
- Early diagnosis of neurodegenerative diseases
- Non-invasive blood testing for biomarkers previously only detectable in CSF
Biomarkers are the key to understanding the intricate mechanisms of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. They not only aid in early diagnosis but also provide essential insights into disease progression, enabling the development of targeted therapies. Yet, traditional methods face significant hurdles in detecting these biomarkers due to the protective blood-brain barrier and the complexity of protein aggregation.
What You'll Learn in This White Paper
- The critical role of biomarkers in neuroscience research
- How BOLD technology enhances standard immunoassay tests
- Case study: Detecting pTau(181) in human plasma with unprecedented sensitivity
- Step-by-step implementation guide for BOLD technology
- Future implications for drug discovery and personalized medicine
By incorporating BOLD Technology into existing assays, researchers have already demonstrated significant improvements in detecting pTau(181), a critical biomarker for Alzheimer’s disease. This enhanced detection capability not only accelerates research but also opens the door to earlier intervention and better patient outcomes.
Why BOLD Technology Matters
- Accessible: Easily integrate into existing immunoassay workflows
- Cost-effective: Achieve ultra-sensitive detection without expensive equipment
- Versatile: Applicable across various neurodegenerative diseases
BOLD Technology, developed by Cavidi, offers a groundbreaking approach to biomarker detection. This ultra-sensitive technology can be integrated into any immunoassay, enhancing the sensitivity by up to 100x and the limit of detection by up to 50x. BOLD Technology empowers researchers to achieve unprecedented accuracy in detecting even the most elusive biomarkers, driving forward the quest for early diagnosis and effective treatment.
“BOLD Technology stands at the forefront of innovation in neuroscience, offering a scalable, cost-effective solution for ultra-sensitive biomarker detection.”
- Excerpt from the white paperDownload the White Paper Now
Discover the implications for your projects. Download the white paper now and stay at the forefront of neuroscience research.
Download your free copy
